Progressive supranuclear palsy

What is Progressive supranuclear palsy?

Progressive supranuclear palsy (PSP) is a rare, degenerative brain disorder that primarily affects movement, balance, and eye function. The condition belongs to a group of diseases called tauopathies, where abnormal tau protein accumulates in brain cells, leading to their deterioration and death. PSP typically affects adults over 60 years of age and has a prevalence of approximately 5-7 cases per 100,000 people. The disease is characterized by distinctive symptoms including difficulty moving the eyes vertically, frequent falls, and muscle stiffness, particularly in the neck and trunk.

Key statistics

Symptoms

Common symptoms: Vertical gaze palsy, frequent falls, axial rigidity, bradykinesia, dysarthria, dysphagia, cognitive impairment, sleep disturbances, depression.

The hallmark symptom of PSP is vertical supranuclear gaze palsy, where patients lose the ability to look up or down voluntarily, though their eyes can still move when the head is tilted. Early falls, often backward, are another distinctive feature that typically occurs within the first year of symptoms. Unlike Parkinson’s disease, PSP patients develop pronounced axial rigidity, causing stiffness in the neck and trunk that gives them a characteristic upright, rigid posture.

Speech problems (dysarthria) develop early, with patients speaking in a slow, slurred manner. Swallowing difficulties (dysphagia) progressively worsen, increasing the risk of aspiration pneumonia. Cognitive changes include executive dysfunction, affecting planning and decision-making abilities, while memory typically remains relatively preserved in early stages.

Submit Your Paper

Sleep disturbances are common, including insomnia and REM sleep behavior disorder. Many patients experience depression and apathy, which can significantly impact quality of life. As the disease progresses, patients may develop pseudobulbar affect, causing inappropriate emotional responses such as sudden laughing or crying.

Causes and risk factors

PSP is primarily a sporadic tauopathy, meaning it occurs randomly without a clear hereditary pattern in about 95% of cases. The disease results from abnormal accumulation of tau protein in specific brain regions, including the brainstem, basal ganglia, and frontal cortex. This protein accumulation leads to neuronal death and brain atrophy.

Only 5-10% of PSP cases have a familial component, with mutations in genes such as MAPT (tau protein gene), MOBP, and STX6 being identified in some families. The C9orf72 gene expansion has also been associated with PSP-like syndromes in rare cases.

Risk factors include advancing age, with most cases occurring after age 60. Men are slightly more affected than women. Some studies suggest potential environmental factors, including exposure to certain toxins or infections, but these associations remain unproven. Head trauma has been proposed as a possible risk factor, but evidence remains inconclusive.

Prevention

Currently, there are no proven methods to prevent PSP, as the vast majority of cases are sporadic with unknown triggers. Since only a small percentage of cases are familial, genetic testing is typically reserved for families with multiple affected members or cases with very early onset.

For individuals with a family history of PSP, genetic counseling can provide information about inheritance patterns and available testing options. However, even in familial cases, predictive testing is complex due to incomplete penetrance and variable expression of genetic variants.

Regular physical exercise, cognitive stimulation, and maintaining overall brain health through proper nutrition and social engagement may support general neurological wellness, though specific preventive benefits for PSP have not been established.

Complications

Without proper management, PSP leads to severe complications that significantly impact survival and quality of life. Swallowing difficulties progressively worsen, leading to aspiration pneumonia, which is a leading cause of death in PSP patients. The inability to cough effectively further increases infection risk.

Frequent falls due to balance problems and gaze palsy can result in serious injuries, including fractures and head trauma. The rigid posture and immobility eventually lead to contractures and pressure sores. Bladder dysfunction becomes common, increasing urinary tract infection risk.

Cognitive decline affects daily functioning and decision-making capacity. Sleep disorders worsen over time, and some patients develop severe insomnia. Depression and apathy can lead to social withdrawal and reduced treatment compliance. In advanced stages, patients typically require full-time care and may develop complications related to immobility and reduced immune function.

Diagnosis

PSP diagnosis relies primarily on clinical criteria, as no single definitive test exists. The Movement Disorder Society has established diagnostic criteria based on core features including ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction.

Brain MRI may show characteristic changes including midbrain atrophy (hummingbird sign) and enlarged third ventricle. DaTscan (dopamine transporter imaging) can help differentiate PSP from other movement disorders. Cerebrospinal fluid analysis may reveal elevated tau protein levels, though this is not specific to PSP.

Neuropsychological testing assesses cognitive function, particularly executive abilities. Speech and swallowing evaluations help document bulbar dysfunction. Sleep studies may identify REM sleep behavior disorder and other sleep abnormalities.

The diagnostic journey can be lengthy and challenging, as PSP symptoms often overlap with Parkinson’s disease, multiple system atrophy, and corticobasal degeneration. Many patients receive initial misdiagnoses, emphasizing the importance of seeking evaluation at specialized movement disorder centers.

Treatment

No cure exists for PSP, and treatment focuses on symptom management and supportive care. Levodopa may provide modest improvement in some movement symptoms, though response is typically limited compared to Parkinson’s disease. Amantadine can help with rigidity and bradykinesia in some patients.

For depression and apathy, selective serotonin reuptake inhibitors like sertraline or citalopram may be beneficial. Sleep disorders may respond to melatonin for insomnia or clonazepam for REM sleep behavior disorder.

Physical therapy is crucial for maintaining mobility, balance, and preventing falls. Speech therapy helps with communication and swallowing safety. Occupational therapy assists with adaptive equipment and home safety modifications. Some patients benefit from weighted walkers or mobility aids to improve stability.

Nutritional support becomes increasingly important as swallowing difficulties progress. In advanced stages, feeding tube placement may be necessary to prevent aspiration and maintain nutrition.

Prognosis

PSP typically progresses more rapidly than Parkinson’s disease, with most patients experiencing significant disability within 3-5 years of symptom onset. Average survival ranges from 6-10 years after symptom onset, though individual variation exists.

Early falls and rapid progression of gaze palsy are associated with faster disease progression. Patients who maintain better cognitive function and have less severe swallowing problems may have somewhat longer survival times.

Quality of life declines progressively due to increasing physical limitations, communication difficulties, and cognitive changes. However, with appropriate supportive care, including physical therapy, speech therapy, and medical management, patients can maintain function longer and experience improved comfort throughout the disease course.

Quality of life

Maintaining quality of life requires a comprehensive, multidisciplinary approach. Regular exercise, adapted to individual abilities, helps preserve mobility and may slow functional decline. Water-based exercises can be particularly beneficial for balance and joint mobility.

Dietary modifications become essential as swallowing difficulties develop. Thickened liquids and soft, easy-to-swallow foods can improve safety. Small, frequent meals may be better tolerated than large meals.

Home safety modifications are crucial to prevent falls, including removing tripping hazards, installing grab bars, improving lighting, and using non-slip surfaces. Weighted utensils and special cups can help with eating independence.

Social engagement and mental stimulation remain important despite cognitive changes. Support groups, either in-person or online, can provide valuable connections with others facing similar challenges. Maintaining hobbies and interests, adapted as needed, supports emotional well-being.

Sleep hygiene practices, including consistent bedtime routines and comfortable sleeping environments, can help manage sleep disturbances. Stress reduction techniques and counseling support mental health throughout the disease progression.

Pregnancy and fertility

PSP rarely affects individuals of reproductive age, as onset typically occurs after age 60. In the uncommon situation where PSP affects younger individuals, pregnancy planning should involve careful medication review and genetic counseling.

Most PSP medications have limited safety data in pregnancy, requiring risk-benefit discussions with healthcare providers. For individuals with familial PSP considering pregnancy, genetic counseling can provide information about inheritance risks and testing options for at-risk pregnancies.

Children

PSP extremely rarely affects children, with only isolated case reports of juvenile-onset disease. When it occurs in young people, it’s typically associated with genetic mutations and may have a different presentation than typical adult-onset PSP.

Children in families affected by familial PSP may benefit from genetic counseling to understand their future risks and available testing options when they reach adulthood.

When to see a doctor

Seek medical evaluation promptly for unexplained frequent falls, particularly backward falls, especially when combined with difficulty moving the eyes up or down. Other concerning symptoms include rapid onset of balance problems, stiffness in the neck and back, slurred speech, or swallowing difficulties.

Urgent medical attention is needed for signs of aspiration pneumonia, including fever, cough, difficulty breathing, or chest pain. Severe depression, suicidal thoughts, or significant cognitive changes also warrant immediate medical evaluation.

Regular follow-up with movement disorder specialists is essential for monitoring disease progression and adjusting treatment plans. Speech and swallowing evaluations should be repeated regularly to assess safety and need for dietary modifications.

Regional context

Limited data exists on PSP prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The condition likely occurs at similar rates to global estimates, but underdiagnosis may be common due to limited access to movement disorder specialists and diagnostic facilities.

Healthcare systems in these regions may benefit from increased awareness of PSP among neurologists and primary care physicians to improve diagnostic accuracy and reduce delays in diagnosis. The Global Medical Journal welcomes contributions from regional healthcare providers regarding their experiences with PSP diagnosis and management in these populations.

Research and clinical trials

Active research focuses on developing disease-modifying treatments targeting tau protein aggregation. Anti-tau antibodies, tau aggregation inhibitors, and neuroprotective compounds are being investigated in clinical trials.

The drug davunetide showed initial promise but failed in phase III trials. Current investigations include compounds targeting microtubule stabilization, neuroinflammation, and cellular waste clearance mechanisms.

Biomarker research aims to develop better diagnostic tools and track disease progression. Advanced imaging techniques, cerebrospinal fluid markers, and blood-based biomarkers are under investigation.

Patients interested in clinical trials can search ClinicalTrials.gov for current studies. The CurePSP organization maintains updated information about research opportunities and helps connect patients with appropriate studies.

Frequently asked questions

Is PSP the same as Parkinson’s disease?

No, while both are movement disorders, PSP differs from Parkinson’s disease in several key ways. PSP typically causes early falls, vertical gaze problems, and responds poorly to levodopa treatment, whereas Parkinson’s usually responds well to levodopa and rarely causes early falls.

Is PSP hereditary?

Most PSP cases (95%) are sporadic and not inherited. Only 5-10% of cases have a familial component with identified genetic mutations. Having a family member with PSP slightly increases risk, but most children of PSP patients will not develop the disease.

How quickly does PSP progress?

PSP typically progresses faster than Parkinson’s disease, with significant disability developing within 3-5 years of symptom onset. However, progression rates vary among individuals, and supportive treatments can help maintain function longer.

Can PSP be cured?

Currently, no cure exists for PSP. Treatment focuses on managing symptoms and maintaining quality of life through medications, therapy, and supportive care. Research continues into potential disease-modifying treatments.

What’s the difference between PSP variants?

PSP has several variants including Richardson’s syndrome (classic PSP), PSP-parkinsonism, PSP-frontal, and others. These variants differ in prominent symptoms and progression rates, but all involve tau protein accumulation in the brain.

Support and resources

CurePSP: www.psp.org – Leading organization for PSP research, education, and patient support
Orphanet: www.orpha.net – European database of rare diseases
National Organization for Rare Disorders (NORD): rarediseases.org
EURORDIS: www.eurordis.org – European rare disease patient advocacy
Movement Disorder Society: www.movementdisorders.org
International Parkinson and Movement Disorder Society: www.movementdisorders.org

Related conditions

Parkinson’s disease
Multiple system atrophy
Corticobasal degeneration
Frontotemporal dementia
Chronic traumatic encephalopathy

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, Movement Disorder Society Clinical Diagnostic Criteria, CurePSP. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.